Trial · NCT04776850
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
NCT04776850, Early phase 1, Withdrawn, M.D. Anderson Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies. Trials, record NCT04776850. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04776850
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- NCT number
- NCT04776850
- Status
- Withdrawn
- Phases
- Early phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
- Interventions
Bortezomib, Busulfan, Cyclophosphamide, Dexamethasone, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Mycophenolate Mofetil, Plasmapheresis, Rituximab, Tacrolimus
- First posted
- 2021-03-02
- Last updated
- 2024-10-24
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival (EFS) | At 2 years post-hematopoietic cell transplantation (HCT) | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. |
| Secondary | Event-free survival | Up to 100 days post-HCT | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. |
| Secondary | Event-free survival | Up to 1 year post-HCT | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. |
| Secondary | Overall survival | Up to 100 days post-HCT | Will be summarized by the Kaplan-Meier method. |
| Secondary | Overall survival | Up to 1 year post-HCT | Will be summarized by the Kaplan-Meier method. |
| Secondary | Transplant-related mortality | Up to 30 days post-HCT | Will be summarized by the Kaplan-Meier method. |
| Secondary | Time to platelet and neutrophil engraftment | Up to 2 years post-HCT | Will be estimated using the method of Gooley et al. |
| Secondary | Incidence of graft failure (primary and secondary) | Up to 100 days post-HCT | Will be estimated using the method of Gooley et al. |
| Secondary | Incidence of acute graft-versus-host disease | Up to 100 days post-HCT | Will be estimated using the method of Gooley et al. |
| Secondary | Incidence of chronic graft-versus-host disease | Up to 1 year post-HCT | Will be estimated using the method of Gooley et al. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04776850
GET https://conductscience.org/api/trials/v1/NCT04776850/registered